MED Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
72.0M
-5.7%
76.4M
+0.4%
76.0M
+1.3%
75.1M
-16.0%
89.4M
Cost of Revenue
22.0M
-4.3%
23.0M
-5.4%
24.3M
+5.8%
23.0M
-15.8%
27.3M
Gross Profit
50.0M
-6.3%
53.4M
+3.2%
51.8M
-0.7%
52.1M
-16.1%
62.2M
Operating Expenses
69.4M
+20.2%
57.7M
+4.9%
55.1M
-8.2%
59.9M
-9.5%
66.2M
R&D
0
0
0
0
0
SG&A
69.4M
+20.2%
57.7M
+4.9%
55.1M
-8.2%
59.9M
-9.5%
66.2M
Operating Income
-19358000
-347.4%
-4327000
-31.3%
-3295000
+57.8%
-7803000
-91.2%
-4081000
EBITDA
-16995000
-1829.1%
-881000
-568.6%
188.0K
+104.3%
-4338000
-589.7%
-629000
Net Income
-17511000
-464.9%
-3100000
-46.1%
-2122000
+88.3%
-18119000
-701.4%
-2261000
EPS (Basic)
$-1.57
-460.7%
$-0.28
-47.4%
$-0.19
+88.5%
$-1.65
-685.7%
$-0.21
EPS (Diluted)
$-1.57
-460.7%
$-0.28
-47.4%
$-0.19
+88.6%
$-1.66
-690.5%
$-0.21
Shares (Diluted)
11.2M
+0.4%
11.1M
+1.2%
11.0M
+0.7%
10.9M
-0.6%
11.0M
Medifast (MED) — Financials